Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:445154
Structure:
Synonyms:
"trans-3,4′,5-trihydroxystilbene"
(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol
(E)-5-(p-Hydroxystyryl)resorcinol
(E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol
(E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol
(E)-resveratrol
1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-
1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-;
3,4',5-Stilbenetriol
3,4',5-trihydroxy-stilbene
3,4',5-Trihydroxy-trans-stilbene
3,4',5-Trihydroxystilbene
3,5,4'-Trihydroxy-trans-stilbene
3,5,4'-Trihydroxystilbene
3,5-Dihydroxy-4'-methoxystilbene
31100-06-8
31100-06-8 (DELETED)
34092_FLUKA
34092_RIEDEL
5-((1E)-2-(4-Hydroxyphenyl)ethenyl)-1,3-benzenediol
5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol
5-[(1E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol
5-[(1E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol
5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol
5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol
5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol
501-36-0
533C1DA0-4104-42B5-9D32-9265F40857E4
AC-727
AC1L9HIC
AIDS-025474
AIDS025474
BB_NC-2570
BPBio1_000479
BRD-K25591257-001-01-2
BRD-K80738081-001-06-2
BRD-K80738081-001-10-4
BSPBio_000435
BSPBio_001114
BSPBio_003461
C03582
C059514
C14H12O3
CCG-38874
CCRIS 8952
CHEBI:27881
CHEBI:45713
CHEMBL165
CPD-83
CPD000058206
CU-01000001503-3
DB02709
EU-0101111
FT-0082623
HMS1362H15
HMS1569F17
HMS1792H15
HMS1921N04
HMS1990H15
HMS2052I09
HMS2096F17
HMS2232A18
HMS3263O04
HSDB 7571
I06-0437
IDI1_002152
KSC-10-164
KUC104385N
LMPK13090005
Lopac0_001111
LS-2146
LUKBXSAWLPMMSZ-OWOJBTEDSA-
MLS000069735
MLS001055357
MLS001076538
MLS002207121
MLS002222231
MolPort-002-499-801
NCGC00017352-05
NCGC00017352-06
NCGC00017352-07
NCGC00017352-08
NCGC00017352-09
NCGC00017352-10
NCGC00017352-11
NCGC00017352-12
NCGC00017352-13
NCGC00017352-14
NCGC00017352-15
NCGC00017352-16
NCGC00017352-17
NCGC00017352-18
NCGC00017352-19
NCGC00024003-00
NCGC00024003-04
NCGC00024003-05
NCGC00024003-06
NCGC00024003-07
NCGC00024003-08
NCGC00024003-09
NCGC00024003-10
NCGC00024003-11
NCGC00024003-12
NCGC00024003-13
NCGC00024003-14
nchembio.140-comp2
nchembio.281-comp10
NSC 327430
NSC327430
Prestwick2_000508
Prestwick3_000508
Prestwick_619
PREVENTION 8 (RESVERATROL)
R 5010
R0071
R5010_SIGMA
Resveratrol
Resveratrol, E-
resveratrol-3-sulfate
Resveratrol-Supplied by Selleck Chemicals
Resvida
RM-1812
RV
S1396_Selleck
SAM001246888
SDCCGMLS-0002998.P003
SGCUT00007
SMR000058206
SPECTRUM1502223
Spectrum5_000552
SRT 501
SRT-501
SRT501
ST057251
STL
TL8003323
to_000079
trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene
trans-3,4′,5-Trihydroxystilbene
trans-3,4',5-trihydroxystilbene
trans-Resveratrol
ZINC00006787

Target

show target details
Uniprot ID:Q9Y354_HUMAN
Synonyms:
Matrix metalloproteinase 9
EC-Numbers:3.4.24.35
Organism:Homo sapiens
Human
PDB IDs:-

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----

References:

14661062
Resveratrol inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting JNK and PKC delta signal transduction.. Ju-Hyung Woo; Jun Hee Lim; Young-Ho Kim; Seong-Il Suh; Do Sik Min; Jong-Soo Chang; Young Han Lee; Jong-Wook Park; Taeg Kyu Kwon (2004) Oncogene display abstract
Proteolytic degradation of the extracellular matrix and tumor metastasis correlate with the expression of endopeptidases known as matrix metalloproteinases (MMPs). The expression of MMPs is regulated by cytokines and signal transduction pathways, including those activated by phorbol myristate acetate (PMA). We found that resveratrol, a phytoalexin present in grapes, significantly inhibits the PMA-induced increase in MMP-9 expression and activity. These effects of resveratrol are dose dependent and correlate with the suppression of MMP-9 mRNA expression levels. PMA caused about a 23-fold increase in MMP-9 promoter activity, which was suppressed by resveratrol. Transient transfection utilizing MMP-9 constructs, in which specific transcriptional factors were mutagenized, indicated that the effects of PMA and resveratrol were mediated via an activator protein-1 and nuclear factor-kappaB response element. Resveratrol inhibited PMA-mediated activation of c-Jun N-terminal kinase (JNK) and protein kinase C (PKC)-delta activation. Therefore, we conclude that the MMP-9 inhibition activity of resveratrol and its inhibition of JNK and PKC-delta may have a therapeutic potential, given that a novel means of controlling growth and invasiveness of tumors.